Just wanted to keep it in context: a lot of water will run under the bridge before Big Pharma buys PVCT. Think months or years, not days or weeks. Or never. I see buyout guesstimates of 50-100 dollars per share. Let's see the FDA minutes first. Let's see the pathway PVCT must take, which will likely entail a trial of some sort. Which means time. Which means money. Which means the possibility of failure.
The first thing new investors are going to want to see after the FDA determines the pathway will be money: where will the money come from to finance the trial. And unless a partnership or licensing agreement comes soon thereafter, I bet the share price languishes, even drops. Watch. Promising biotechs are a dime-a-dozen. Money isn't.
I quote Motley Fool on the sucess of micro-cap phase 3 oncology trial sucess:
"Although the ranks of extremist biotech investors don't like to admit it, the Feuerstein-Ratain Rule has a perfect record when predicting micro-cap phase 3 oncology trial success. The rule is named after Adam Feuerstein, a senior columnist at TheStreet.com, and Dr. Mark Ratain, an oncologist from the University of Chicago, who published a study in JNCI in October 2011 explaining their observations. After looking at the outcomes of 58 phase 3 cancer trials over the past 10 years, the pair found that companies with a market cap less than $300 million several months before the release of trial results were 0-for-21, whereas companies with a market cap exceeding $1 billion were a respectable 21-for-27. Ouch."
300m several months before release of phase 3 trail results. Hmmmm.
Every biotech investor has that ONE company. Well, so far the man every biotech extremist loves to hate is 0-for-21. Let's keep things in perspective, have an open mind, and hope for the best.
News 
Market Data 
Discover 
